Rotavirus Vaccination: Cost-Effectiveness and Impact on Child Mortality in Developing Countries
This article, published in The Journal of Infectious Diseases, aimed to project the uptake, health impact, and cost-effectiveness of introducing rotavirus vaccination in GAVI-eligible countries. The authors used a demand forecast model to predict adoption of rotavirus vaccine in the poorest countries in the world. They then modeled health outcomes and direct costs of a hypothetical birth cohort in the target population for scenarios with and without a rotavirus vaccine with use of data on health outcomes of rotavirus infection, vaccine effectiveness, and immunization rates. The results indicated that vaccination would prevent 2.4 million rotavirus deaths and more than 82 million disability-adjusted life-years in 64 of the 72 GAVI-eligible countries introducing vaccine from 2007 through 2025. In addition, introduction of rotavirus vaccines would be very cost-effective in all GAVI-eligible countries.
Author(s): Atherly D, Dreibelbis R, Parashar UD, Levin C, Wecker J, Rheingans RD
Visit web page (English)
(Located at jid.oxfordjournals.org)
Citation: Atherly D, Dreibelbis R, Parashar UD, Levin C, Wecker J, Rheingans RD. Rotavirus Vaccination: Cost-Effectiveness and Impact on Child Mortality in Developing Countries. The Journal of Infectious Diseases. 2009;200(Suppl 1):S28-S38.